Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05389215 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
A Phase 2 study of Idiopathic Pulmonary Fibrosis, sponsored by Daewoong Pharmaceutical Co..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
- 20
- Study locations
NCT05389215: Recruiting Phase 2 study of Idiopathic Pulmonary Fibrosis, sponsored by Daewoong Pharmaceutical Co..
NCT05389215 is a Phase 2 study of Idiopathic Pulmonary Fibrosis that is actively recruiting participants, run by Daewoong Pharmaceutical Co.. The registered enrollment target is 102 participants, below the 750-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05389215, a Phase 2 study of Idiopathic Pulmonary Fibrosis, is actively recruiting participants, sponsored by Daewoong Pharmaceutical Co..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis.
Primary Outcome
To investigate the efficacy of DWN12088 on pulmonary function
Conditions Studied
Interventions
- DRUG Placebo
- DRUG DWN12088
Study Locations (20)
Texas
- Baylor Scott & White Research Institute - Dallas
- The University of Texas Southwestern Medical Center - Dallas
- Baylor College of Medicine - Houston
- The University of Texas Health San Antonio Medical Arts & Research Center - San Antonio
Arizona
- Pulmonary Associates, PA - Mesa
- Dignity Health Norton Thoracic Institute - Phoenix
Massachusetts
- Tufts Medical Center - Boston
- Beth Israel Deaconess Medical Center - Boston
North Carolina
- Duke University Medical Center - Durham
- Pulmonix Research, LLC - Greensboro
Pennsylvania
- Penn State Milton S. Hershey Medical Center - Hershey
- University of Pittsburgh Medical Center - Pittsburgh
South Carolina
- The U.S. Department of Veterans Affairs - Charleston
- Lowcountry Lung and Critical Care - Charleston
California
- The University of California San Francisco - San Francisco
Illinois
- Loyola University Medical Center (LUMC) - Maywood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2022-07-29 |
| Est. Completion | 2027-01-30 |
| Phase | Phase 2 |
What NCT05389215 shows while recruiting
NCT05389215 is an interventional study that assigns participants to a tested intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, below the 750-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05389215 names 20 study sites across 12 states, led by Texas, Arizona, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05389215 about?
NCT05389215 is a clinical study titled "Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF". This is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis.
What is the current status of trial NCT05389215?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2022-07-29. Estimated completion is 2027-01-30.
What conditions does trial NCT05389215 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis.
What interventions are being tested in trial NCT05389215?
The interventions under investigation include: Placebo (DRUG), DWN12088 (DRUG).
Who is sponsoring clinical trial NCT05389215?
This trial is sponsored by Daewoong Pharmaceutical Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05389215 being conducted?
This trial has 20 study locations across Arizona, California, Illinois, Kansas, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05389215's enrollment target sits among peer trials
102 21st of 51 higher than 31 of 51 other Idiopathic Pulmonary Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Idiopathic Pulmonary Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
RECRUITING · Phase 2
-
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
RECRUITING · Phase 2
-
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
RECRUITING · Phase 2
-
H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704662 · 102 participants · NA
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
- NCT04174742 · 102 participants
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
- NCT04275362 · 102 participants
Gait Analysis of a Lateral-Pivot Design Total Knee Replacement
- NCT04541082 · 102 participants · Phase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI